TY - JOUR
T1 - Assessment of patient-reported outcomes (PROs)
T2 - treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea
AU - Byun, Dong Won
AU - Moon, Seong Hwan
AU - Kim, Tak
AU - Lee, Hae Hyeog
AU - Park, Hyoung Moo
AU - Kang, Moo Il
AU - Ha, Yong Chan
AU - Chung, Ho Yeon
AU - Yoon, Byung Koo
AU - Kim, Tae Young
AU - Chae, Soo Uk
AU - Shin, Chan Soo
AU - Yang, Kyu Hyun
AU - Lee, Jae Hyup
AU - Chang, Jae Suk
AU - Kim, Sung Hoon
AU - Kim, In Joo
AU - Koh, Jung Min
AU - Jung, Jung Hwa
AU - Yi, Kyong Wook
AU - Yoo, Jeong Joon
AU - Chung, Dong Jin
AU - Lee, Young Kyun
AU - Yoon, Hyun Koo
AU - Hong, Seongbin
AU - Kim, Deog Yoon
AU - Baek, Ki Hyun
AU - Kim, Hyun Joo
AU - Kim, Young Joo
AU - Kang, Seongsik
AU - Min, Yong Ki
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.
AB - Patient-reported outcomes (PROs) provide practical guides for treatment; however, studies that have evaluated PROs of women in Korea with postmenopausal osteoporosis (PMO) are lacking. This cross-sectional, multi-center (29 nationwide hospitals) study, performed from March 2013 to July 2014, aimed to assess PROs related to treatment satisfaction, medication adherence, and quality of life (QoL) in Korean PMO women using osteoporosis medication for prevention/treatment. Patient demographics, clinical characteristics, treatment patterns, PROs, and experience using medication were collected. The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) (score-range, 0–100; domains: effectiveness, side effects, convenience, global satisfaction), Osteoporosis-Specific Morisky Medication Adherence Scale (OS-MMAS) (score-range, 0–8), and EuroQol-5 dimensions questionnaire (index score range, − 0.22 to 1.0; EuroQol visual analog scale score range, 0–100) were used. To investigate factors associated with PROs, linear (treatment satisfaction/QoL) or logistic (medication adherence) regression analyses were conducted. A total of 1804 patients (age, 62 years) were investigated; 60.1% used bisphosphonate, with the majority (67.2%) using weekly medication, 27.8% used daily hormone replacement therapy, and 12.1% used daily selective estrogen receptor modulator. Several patients reported gastrointestinal (GI) events (31.6%) and dental visits due to problems (24.1%) while using medication. Factors associated with the highest OS-MMAS domain scores were convenience and global satisfaction. GI events were associated with non-adherence. TSQM scores for effectiveness, side effects, and GI risk factors were significantly associated with QoL. Our study elaborately assessed the factors associated with PROs of Korean PMO women. Based on our findings, appropriate treatment-related adjustments such as frequency/choice of medications and GI risk management may improve PROs.
KW - Gastrointestinal events
KW - Medication adherence
KW - Postmenopausal osteoporosis
KW - Quality of life
KW - Treatment satisfaction
UR - http://www.scopus.com/inward/record.url?scp=85053797997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053797997&partnerID=8YFLogxK
U2 - 10.1007/s00774-018-0956-6
DO - 10.1007/s00774-018-0956-6
M3 - Article
C2 - 30238428
AN - SCOPUS:85053797997
VL - 37
SP - 563
EP - 572
JO - Journal of Bone and Mineral Metabolism
JF - Journal of Bone and Mineral Metabolism
SN - 0914-8779
IS - 3
ER -